Horn & Co. represented Pontifax Ventures on the deal.
Pontifax Venture Capital and Kreos Capital provided €10 million debt financing to Oxurion.
Oxurion is focused on building a leading global franchise in the treatment of retinal vascular disorders based on the successful development of its two novel therapeutics.
The Horn & Co. team was led by Yonatan Levinstein (Picture).
Involved fees earner: Yonatan Levinstein – Horn & Co. Law;
Law Firms: Horn & Co. Law;